Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Payables (2021 - 2026)

Envoy Medical's Payables history spans 6 years, with the latest figure at $6.8 million for Q1 2026.

  • On a quarterly basis, Payables rose 310.83% to $6.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $6.8 million, a 310.83% increase, with the full-year FY2025 number at $6.7 million, up 185.87% from a year prior.
  • Payables hit $6.8 million in Q1 2026 for Envoy Medical, up from $6.7 million in the prior quarter.
  • Over the last five years, Payables for COCH hit a ceiling of $7.4 million in Q3 2023 and a floor of $658899.0 in Q1 2022.
  • Historically, Payables has averaged $2.7 million across 5 years, with a median of $1.6 million in 2024.
  • Biggest five-year swings in Payables: surged 588.95% in 2023 and later tumbled 76.2% in 2024.
  • Tracing COCH's Payables over 5 years: stood at $1.5 million in 2022, then increased by 7.1% to $1.6 million in 2023, then skyrocketed by 50.77% to $2.3 million in 2024, then skyrocketed by 185.87% to $6.7 million in 2025, then rose by 1.94% to $6.8 million in 2026.
  • Business Quant data shows Payables for COCH at $6.8 million in Q1 2026, $6.7 million in Q4 2025, and $5.3 million in Q3 2025.